WallStSmart

Lexicon Pharmaceuticals Inc (LXRX)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 160427% more annual revenue ($66.57B vs $41.47M). MRK leads profitability with a 4.8% profit margin vs -147.4%. MRK earns a higher WallStSmart Score of 36/100 (F).

LXRX

Avoid

16

out of 100

Grade: F

Growth: 3.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: -14.39

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LXRX.

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LXRX0 strengths · Avg: 0/10

No standout strengths identified

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

LXRX4 concerns · Avg: 2.3/10
Market CapQuality
$1.01B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-12.9%2/10

ROE of -12.9% — below average capital efficiency

Revenue GrowthGrowth
-97.6%2/10

Revenue declined 97.6%

EPS GrowthGrowth
-63.4%2/10

Earnings declined 63.4%

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : LXRX

LXRX has a balanced fundamental profile.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : LXRX

The primary concerns for LXRX are Market Cap, Return on Equity, Revenue Growth.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

LXRX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

LXRX carries more volatility with a beta of 1.03 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 16/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lexicon Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?